Sign in
Taking people in United StatesNo phase

Studies genetic factors behind several lung diseases in patients and healthy volunteers

Looks at genes in people with cystic fibrosis, asthma and other lung diseases.

Key facts

Who runs it
National Heart, Lung, and Blood Institute (NHLBI)
Where
Bethesda, United StatesSee the 2 sites
Trial code
Registry title
Role of Genetic Factors in the Development of Lung Disease
Status
Recruiting
People taking part
3,500 people, planned
Started
13 Sept 1996
Type of study
Observational, 2 groups
Record updated
9 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with lung diseases, such as cystic fibrosis, asthma, sarcoidosis, pulmonary fibrosis or tuberous sclerosis, and also healthy volunteers and relatives of patients, to study genes in lung disease.

Age
From 2 years to 90 years. Most people must be 18 to 90. Some children with certain conditions can join from 2 years old, 8 years old or 16 years old.
Sex
All sexes can join.
Disease stage
Established diagnosis of a lung disease or related disorder, with symptoms, chest x-ray and lung function tests consistent with lung disease. Healthy volunteers and control groups without lung disease can also join.
Biomarker or test result
For cystic fibrosis: a known CFTR gene change such as the delta F508 allele, or a cystic fibrosis phenotype with matching clinical features. For AAT deficiency: a confirmed high risk phenotype. For some children: a known defect in ADP-ribosylation.

Main reasons for not taking part

  • Age under 18 or over 90, except for the listed younger patients
  • Cannot do reliable lung function tests
  • For the bronchoscopy part: any reason a bronchoscopy cannot be done safely
  • For the bronchoscopy part: allergy to topical anesthetic such as lidocaine
  • For the bronchoscopy part: respiratory infection in the last 4 weeks, or pregnancy or breastfeeding

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • symptoms consistent with pulmonary disease
  • chest x-ray consistent with pulmonary disease
  • pulmonary function tests consistent with pulmonary disease
  • smokers, defined as individuals who are current smokers (1 pack per day for at least 2 years) and nonsmokers, defined as never-smokers or ex-smokers who have not smoked for three or more years
  • Patients with established diagnoses of sarcoidosis; mycobacterial infections; TSC (definite or possible); cystic lung diseases including genetic diseases; lymphangioleiomyomatosis or diseases associated with lymphatic disorders; history of pneumothorax; pulmonary fibrosis; asthma; histiocytosis X and diabetes mellitus will be included in this protocol. Relatives of patients may also be seen under this protocol. Children with lymphangiomatosis who are two years of age or older may be included. Participants with asthma may be enrolled at Suburban Hospital
  • Research volunteers in the pulmonary control group are defined as individuals with no pulmonary disease (e.g. rheumatoid arthritis without evidence of pulmonary disease). Research volunteers in the diabetes control group are defined as individuals with no history of diabetes, coronary artery disease, or pulmonary disease
  • Pregnant and or nursing women can be included in accordance with Federal Regulations at Subpart B of 45 CFR 46. Subjects who are pregnant and or nursing will be excluded from procedures during their pregnancy that are greater than minimal risk, until they are no longer pregnant and/or nursing. Procedures that will not be completed while the subject is pregnant and/or nursing including: PFTs, Six Minute Walk Test, thoracentesis, bronchoscopy, and measurements with imaging modalities requiring contrast or with radiation exposure such as Chest x-ray, CT scan, MRI. Allowing subjects to be included in the study may glean important information about individuals with uncommon pulmonary disease during and post pregnancy
  • Patients with abnormalities in ADP-ribosyltransferases, ADP-ribosyl-acceptor hydrolases, and their substrates. Children who are two years of age or older may be studied if they have a known defect in ADP-ribosylation, or if they have a family member with a defect in ADP-ribosylation and may be affected

Who cannot take part

  • advanced stage of a pulmonary or a systemic illness such that the risk is judged to be significant even in the absence of a specific contraindication to the procedure
  • allergy to topical anesthetic (e.g., lidocaine)
  • current or recent respiratory infection (within the last 4 weeks)
  • age less than 18 or greater than 90 except for NIH patients with diseases /disorders as described in this protocol (except cystic fibrosis, lymphangiomatosis or defects in ADP-ribosylation) who are 16 years of age or older, patients with cystic fibrosis who are over eight years of age, patients who are two years of age or older with lymphangiomatosis or a known defect in ADP-ribosylation, or who have a family member with a defect in ADP-ribosylation, or unless patient-specific IRB approval is obtained and
  • inability to obtain reliable pulmonary function testing. As clarification, healthy volunteers, relatives of patients (except as noted for an ADP-ribosylation defect), and asthmatic patients from Suburban Hospital will be excluded if less than 18 or greater than 90 years of age
  • age less than 18 or greater than 65
  • presence of any contraindication for fiberoptic bronchoscopy, with lavage and/or bronchial brushing
  • pregnancy or lactation

Other criteria

  • INCLUSION CRITERIA:

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 2 and 90 years old?

Where in United States

  • National Institutes of Health Clinical CenterBethesda, United StatesContact: Tatyana Worthy, B.S.Taking people
  • Suburban HospitalBethesda, United StatesContact: Tatyana A Worthy, R.N.No longer taking part

About the trial

What the trial wants to find out

This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease.

Read full original descriptionShow less

The study will focus on defining the distribution of abnormal genes responsible for processes directly involved in different diseases affecting the lungs of patients and healthy volunteers.

Optional CT Sub-study

The standard CT scan will be compared to the low dose radiation CT scan for the 150 subjects enrolled in the sub-study to assess the variation between the two techniques. Specifically, the quantitative computer aided detection of lung CT abnormalities from LAM can be compared to assess whether low radiation dose CT exams is an alternative to conventional CT to monitor disease

status.

This optional sub-study will be offered to up to 100 adult subjects with lung disease and up to 50 children age 9 and older with CF. Children will not be enrolled in the optional CT sub-study unless they have had a standard CT scan for medical purposes to use in comparison. One additional low dose radiation CT scan of the chest may be done as part of this sub-study when these subjects have their next annual CT scan.

The 2 groups in the trial

  • 1

    Subjects with pulmonary disease or possible pulmonary disease and Relatives

  • 2

    Healthy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Role of Genetic Factors in the Pathogenesis of Lung Disease
Plain-language title
Studies genetic factors behind several lung diseases in patients and healthy volunteersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT00001532, who can take part
Record updated
9 November 2026